Skip to main content

Table 3 Prevalence of demographic and clinical characteristics and 95% confidence intervals in youth with opioid use disorder (OUD) with and without documented treatment with medications for OUD (N = 2131)

From: Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems

 

Medication treatmenta (n = 752)

%, (95% CI)

No treatment (n = 1379)

%, (95% CI)

Female

38 (35, 42)

42 (39, 45)

Race/ethnicity

 Hispanic

8.8 (6.9, 11)

8.7 (7.3, 10)

 Caucasian

79 (76, 82)

76 (74, 78)

 Black/African American

1.9 (1.0, 3.1)

3.8 (2.9, 5)

 Asian

1.2 (0.5, 2.3)

2.0 (1.4, 2.9)

 NA/AN

0.5 (0.1, 1.4)

0.7 (0.3, 1.3)

 Hawaiian/Pacific Islander

0.8 (0.3, 1.7)

0.1 (0.02, 0.5)

 Multiracial

3.9 (2.6, 5.5)

5.1 (4, 6.4)

 Other

0.8 (0.3, 1.7)

0.9 (0.5, 1.6)

 Unknown

3.1 (1.9, 4.6)

2.7 (1.9, 3.7)

Insuranceb

 Medicare

11 (8.7, 13)

13 (11, 16)

 Commercial

85 (83, 88)

81 (78, 83)

 State subsidized

0 (0, 0.5)

0.2 (0.02, 0.7)

 Uninsured

3.8 (2.5, 5.4)

5.6 (4.3, 7.2)

Tobacco UD

56 (52, 59)

52 (50, 55)

Alcohol UD

21 (18, 24)

26 (24, 29)

Cannabis UD

34 (31, 38)

32 (30, 35)

Stimulant UD

30 (26, 33)

27 (25, 29)

OD

3.3 (2.2, 4.9)

3.7 (2.8, 4.8)

Depression

36 (32, 39)

48 (45, 50)

Anxiety

42 (38, 45)

50 (48, 53)

Serious mental illnessc

6.9 (5.2, 9.0)

12 (10, 14)

ADD

11 (9.1, 14)

14 (12, 16)

Eating disorder

0.8 (0.3, 1.7)

2.5 (1.8, 3.5)

  1. NA/AN Native American/Alaskan American, OD opioid overdose, UD use disorders, ADD attention deficit disorder
  2. Bolded results are significant at p < 0.05
  3. aOne or more prescriptions or procedure codes for buprenorphine and/or naltrexone in the fiscal year of index visit
  4. bExcludes one health system with missing insurance data
  5. c Serious mental illness defined as schizophrenia and bipoloar disorder